CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

68Ga-DX600 PET/CTWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.23
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.23

There is one clinical trial.

Clinical Trials

1 Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

NCT04422457 Solid Tumor Other: 68Ga-DX600 PET/CT

Primary Outcomes

Description: The uptake of uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）

Measure: SUV

Time: 2 years

No related HPO nodes (Using clinical trials)